# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Francois Brisebois reiterates Entrada Therapeutics (NASDAQ:TRDA) with a Outperform and maintains $25 pri...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA) with a Buy and maintains $1...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Entrada Therapeutics (NASDAQ:TRDA) with a Buy and lowers the pr...
Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patient...
ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no cl...